Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or OpenAthens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Letter to Dermatology

Free Access

The Magnitude of mTORC1 Signalling May Predict the Response to Isotretinoin Treatment in Patients with Hidradenitis Suppurativa

De Vita V.a · Melnik B.C.b

Author affiliations

aDermatology Unit, University of Naples Federico II, Naples, Italy; bDepartment of Dermatology, Environmental Medicine and Health Theory, University of Osnabrück, Osnabrück, Germany

Corresponding Author

Valerio De Vita

Dermatology Unit, Department of Clinical Medicine and Surgery

University of Naples Federico II, Via Sergio Pansini, 5

IT-80131 Naples (Italy)

E-Mail valeriodevita@yahoo.it

Related Articles for ""

Dermatology 2017;233:399–400

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.




First-Page Preview
Abstract of Letter to Dermatology

References

  1. Huang CM, Kirchhof MG: A new perspective on isotretinoin treatment of hidradenitis suppurativa: a retrospective chart review of patient outcomes. Dermatology 2017;233:120-125.
  2. Boer J: Are there indications for isotretinoin treatment of hidradenitis suppurativa? Dermatology 2017;233:111-112.
  3. Zouboulis CC, Desai N, Emtestam L, et al: European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015;29:619-644.
  4. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 2006;124:471-484.
  5. Hay N: Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta 2011;1813:1965-1970.
  6. Dazert E, Hall MN: mTOR signaling in disease. Curr Opin Cell Biol 2011;23:744-755.
  7. Linke M, Fritsch SD, Sukhbaatar N, et al: mTORC1 and mTORC2 as regulators of cell metabolism in immunity. FEBS Lett. 2017;591:3089-3103.
  8. Nagai S, Kurebayashi Y, Koyasu S: Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation. Ann NY Acad Sci 2013;1280:30-34.
  9. Ren W, Yin J, Duan J, et al: mTORC1 signaling and IL-17 expression: defining pathways and possible therapeutic targets. Eur J Immunol 2016;46:291-299.
  10. Moran B, Sweeney CM, Hughes R, et al: Hidradenitis suppurativa is characterised by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy. J Invest Dermatol 2017;137:2389-2395.
  11. Balato A, Di Caprio R, Lembo S, et al: Mammalian target of rapamycin in inflammatory skin conditions. Eur J Inflamm 2014;12:341-350.
  12. Monfrecola G, Lembo S, Caiazzo G, et al: Mechanistic target of rapamycin (mTOR) expression is increased in acne patients' skin. Exp Dermatol 2016;25:153-155.
  13. Monfrecola G, Balato A, Caiazzo G, et al: Mammalian target of rapamycin, insulin resistance and hidradenitis suppurativa: a possible metabolic loop. J Eur Acad Dermatol Venereol 2016;30:1631-1633.
  14. Melnik BC: Is nuclear deficiency of FoxO1 due to increased growth factor/PI3K/Akt-signalling in acne vulgaris reversed by isotretinoin treatment? Br J Dermatol 2010;162:1398-1400.
  15. Melnik BC: The role of transcription factor FoxO1 in the pathogenesis of acne vulgaris and the mode of isotretinoin action. G Ital Dermatol Venereol 2010;145:559-571.
  16. Melnik BC: Isotretinoin and FoxO1: a scientific hypothesis. Dermatoendocrinol 2011;3:141-165.
  17. Melnik BC, Schmitz G: Are therapeutic effects of antiacne agents mediated by activation of FoxO1 and inhibition of mTORC1? Exp Dermatol 2013;22:502-504.
  18. Melnik BC: Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Derm Venereol 2017;97:173-181.
  19. Melnik BC: p53: key conductor of all anti-acne therapies. J Transl Med 2017;15:195.
  20. Botchkareva NV, Ahluwalia G, Shander D: Apoptosis in the hair follicle. J Invest Dermatol 2006;126:258-264.
  21. Kmieć ML, Pajor A, Broniarczyk-Dyła G: Evaluation of biophysical skin parameters and assessment of hair growth in patients with acne treated with isotretinoin. Postepy Dermatol Alergol 2013;30:343-349.
  22. Chen W, Plewig G: Should hidradenitis suppurativa/acne inversa best be renamed as “dissecting terminal hair folliculitis?” Exp Dermatol 2017;26:544-547.
  23. Melnik BC, John SM, Plewig G: Acne: risk indicator for increased body mass index and insulin resistance. Acta Derma Venereol 2013;93:644-649.
  24. Theut Riis P, Marie Saunte D, Benhadou F, et al: Low and high body mass index in hidradenitis suppurativa patients - different subtypes? J Eur Acad Dermatol Venereol 2017; DOI: 10.1111/jdv.14599.
  25. Saxton RA, Sabatini DM: mTOR signaling in growth, metabolism, and disease. Cell 2017;168:960-976.
  26. Melnik BC, Schmitz G: Metformin: an inhibitor of mTORC1 signaling. J Endocrinol Diabetes Obes 2014;2:1029.
  27. Fabbrocini G, Izzo R, Faggiano A, et al: Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. Clin Exp Dermatol 2016;41:38-42.
  28. Verdolini R, Clayton N, Smith A, et al: Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol 2013;27:1101-1108.

Article / Publication Details

Published online: December 20, 2017
Issue release date: February 2018

Number of Print Pages: 2
Number of Figures: 0
Number of Tables: 0

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

References

  1. Huang CM, Kirchhof MG: A new perspective on isotretinoin treatment of hidradenitis suppurativa: a retrospective chart review of patient outcomes. Dermatology 2017;233:120-125.
  2. Boer J: Are there indications for isotretinoin treatment of hidradenitis suppurativa? Dermatology 2017;233:111-112.
  3. Zouboulis CC, Desai N, Emtestam L, et al: European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015;29:619-644.
  4. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 2006;124:471-484.
  5. Hay N: Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta 2011;1813:1965-1970.
  6. Dazert E, Hall MN: mTOR signaling in disease. Curr Opin Cell Biol 2011;23:744-755.
  7. Linke M, Fritsch SD, Sukhbaatar N, et al: mTORC1 and mTORC2 as regulators of cell metabolism in immunity. FEBS Lett. 2017;591:3089-3103.
  8. Nagai S, Kurebayashi Y, Koyasu S: Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation. Ann NY Acad Sci 2013;1280:30-34.
  9. Ren W, Yin J, Duan J, et al: mTORC1 signaling and IL-17 expression: defining pathways and possible therapeutic targets. Eur J Immunol 2016;46:291-299.
  10. Moran B, Sweeney CM, Hughes R, et al: Hidradenitis suppurativa is characterised by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy. J Invest Dermatol 2017;137:2389-2395.
  11. Balato A, Di Caprio R, Lembo S, et al: Mammalian target of rapamycin in inflammatory skin conditions. Eur J Inflamm 2014;12:341-350.
  12. Monfrecola G, Lembo S, Caiazzo G, et al: Mechanistic target of rapamycin (mTOR) expression is increased in acne patients' skin. Exp Dermatol 2016;25:153-155.
  13. Monfrecola G, Balato A, Caiazzo G, et al: Mammalian target of rapamycin, insulin resistance and hidradenitis suppurativa: a possible metabolic loop. J Eur Acad Dermatol Venereol 2016;30:1631-1633.
  14. Melnik BC: Is nuclear deficiency of FoxO1 due to increased growth factor/PI3K/Akt-signalling in acne vulgaris reversed by isotretinoin treatment? Br J Dermatol 2010;162:1398-1400.
  15. Melnik BC: The role of transcription factor FoxO1 in the pathogenesis of acne vulgaris and the mode of isotretinoin action. G Ital Dermatol Venereol 2010;145:559-571.
  16. Melnik BC: Isotretinoin and FoxO1: a scientific hypothesis. Dermatoendocrinol 2011;3:141-165.
  17. Melnik BC, Schmitz G: Are therapeutic effects of antiacne agents mediated by activation of FoxO1 and inhibition of mTORC1? Exp Dermatol 2013;22:502-504.
  18. Melnik BC: Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Derm Venereol 2017;97:173-181.
  19. Melnik BC: p53: key conductor of all anti-acne therapies. J Transl Med 2017;15:195.
  20. Botchkareva NV, Ahluwalia G, Shander D: Apoptosis in the hair follicle. J Invest Dermatol 2006;126:258-264.
  21. Kmieć ML, Pajor A, Broniarczyk-Dyła G: Evaluation of biophysical skin parameters and assessment of hair growth in patients with acne treated with isotretinoin. Postepy Dermatol Alergol 2013;30:343-349.
  22. Chen W, Plewig G: Should hidradenitis suppurativa/acne inversa best be renamed as “dissecting terminal hair folliculitis?” Exp Dermatol 2017;26:544-547.
  23. Melnik BC, John SM, Plewig G: Acne: risk indicator for increased body mass index and insulin resistance. Acta Derma Venereol 2013;93:644-649.
  24. Theut Riis P, Marie Saunte D, Benhadou F, et al: Low and high body mass index in hidradenitis suppurativa patients - different subtypes? J Eur Acad Dermatol Venereol 2017; DOI: 10.1111/jdv.14599.
  25. Saxton RA, Sabatini DM: mTOR signaling in growth, metabolism, and disease. Cell 2017;168:960-976.
  26. Melnik BC, Schmitz G: Metformin: an inhibitor of mTORC1 signaling. J Endocrinol Diabetes Obes 2014;2:1029.
  27. Fabbrocini G, Izzo R, Faggiano A, et al: Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. Clin Exp Dermatol 2016;41:38-42.
  28. Verdolini R, Clayton N, Smith A, et al: Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol 2013;27:1101-1108.

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.